Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisine and E-cigarettes for Smoking Cessation
NCT05311085Phase 3Completed
- Sponsor
- The University of Auckland
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of cytisinicline, nicotine in Tobacco Use Disorder (TUD), sponsored by The University of Auckland. Started May 2022; status: completed.
02
Drugs
cytisiniclinenicotine
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT05311085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05311085.